How does ketamine treatment affect adults with depression compared to standard antidepressant treatment
Evidence Table for PICO question: How does ketamine treatment affect adults with depression compared to standard antidepressant treatment
create evidence Table
2 studies attached that needs to be reviewed and utilized in the attached evidence table template.
i have also included the rubric for this table and article appraisal table
Evidence Table Template
Group Member Names:
PICOT Question: How does ketamine treatment affect adults with depression compared to standard antidepressant treatment
Author (Year) Design/
Sample/ Setting Major Variables
Measurement of DV Results Strength of the Evidence
Ng et al., (2021) randomized-controlled trials
A systematic evaluation of clinical trials reported subjective or objective ratings of general functioning as main or secondary primaries.
Total N i.e Total Research selection= (270 Studies)
Intervention Group N, ie. Studies assessed for eligibility = (14 Articles)
Control Group N, i.e., Studies included in the qualitative synthesis= (6 Articles)
IV: Ketamin/esketamine interventions
DV: General functionality for patients diagnosed with Treatment reresistantepression The outcome i.e. improved general functionality, was assessed across psychosocial and workplace functioning across disparate functional measures, which were the Sheeran Disability Test (SDT) and Endicott Work Productivity Scale (EWPS) The systematic review issued an article relevant across all variables for the predetermined research parameters, i.e. the comparison of ketamine/esketamine intervention with other placebo groups of antidepressants. The results from the identified research study predetermined a significant benefit within the parameters of general functionality for patients within four weeks of ketamine/esketamine administration. The evidence is conclusively associated with the research question of whether ketamine/esketamine is effective compared to other associated antidepressants in managing treatment-resistant disorders.
Marcantoni, et al., (2020) Randomized Control Trials.
The SR and meta-analysis were created using a specified process, which is accessible upon request, and were reported using the Preferred Reporting Items for Systematic Reviews and Meta-analyses: Total N i.e Total studies included (7576)
Intervention Group N =Studies assessed for eligibility= 594
Control Group N = Studies included in metaanalysis= (19)
IV: Intravenous Ketamine Infusion
DV: Effects on depression scores, clinical remission, response rate and efficacy in both time and frequency Meta-analysis was conducted using a random-effects model to investigate changes in standardized mean differences and odds ratios of outcome measures at 4 hours, 24 hours, and 7 days after infusion. Within 4 hours of a single infusion, a substantial ketamine effect was identified, which peaked at 24 hours, and ketamine’s efficacy was still present. 7 days after the injection, the effects are starting to fade. The ketamine impact was amplified and maintained after many administrations. The evidence issued by the meta-analysis does not coincide with th research parameters for the comparison of ketamine/esketamine with other antidepressants in the management of treatment-resistant depression
Ng, J., Rosenblat, J.D., Lui, L.M.W., Teopiz, K.M., Lee, Y., Lipsitz, O., Mansur, R.B., Rodriguez, B.N., Nasri, F., Gill, H., Cha, D.S., Subramaniapillai, M. Ho, R.C., Cao, B., and Mclntyre, R.S. (2021). Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2021.06.032
Marcantoni, W.S., Akoumba, B.S., Wassef, M., Mayrand, J., Lai, H., Richard-Devantoy, S., and Beauchamp, S. (2020). A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment-resistant depression: January 2009 –January 2019. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2020.09.007